IBA SA Reports Stable Backlog, RadioPharma Momentum in Q1 2026
Event summary
- IBA SA reports a stable backlog of €1.6 billion, with €0.73 billion in equipment and €0.83 billion in services.
- RadioPharma Solutions and Proton Therapy drive commercial momentum, with seven systems sold in Q1 2026.
- PanTera achieves three key regulatory milestones for pharmaceutical-grade actinium-225 supply.
- ConformalFLASH® submission to the FDA for first-in-human clinical trial expected by end H1 2026.
- Share buyback program ongoing, with 279,188 shares purchased as of May 15, 2026.
The big picture
IBA SA's Q1 2026 update highlights solid commercial momentum driven by RadioPharma Solutions and Proton Therapy, reflecting broader industry trends in advanced radiation therapy and radiopharmaceuticals. The company's stable backlog and reaffirmed EBIT guidance underscore confidence in its full-year outlook, while regulatory milestones and innovation progress position it for long-term growth. The strategic focus on scaling international customer coverage and service, particularly in the US, aligns with the company's mid-term revenue growth targets.
What we're watching
- Commercial Momentum
- Whether IBA can sustain the strong pipeline in Proton Therapy and convert it into revenue later in the year.
- Regulatory Approvals
- The pace at which PanTera's regulatory milestones will support clinical partners in targeted alpha therapy programs.
- Innovation Impact
- How the submission of ConformalFLASH® to the FDA will affect the timeline for first-in-human clinical trials.
Related topics